Median Technologies announces expansion of its Patient Care business with release of MediScan

NewsGuard 100/100 Score

Median Technologies, The Imaging Phenomics Company® announces today that it is expanding its Patient Care business with the release of MediScan®, a comprehensive portfolio of advanced clinical applications for the automated detection, quantification and monitoring of cancerous or suspicious lesions diagnosed in CT scans.

Median Technologies intends to leverage Mediscan® for strengthening the commercial development and market penetration of its application portfolio in Asia and more specifically in China. Median also plans to focus on the commercial development of Mediscan® in Europe by leveraging its legacy hospital-based radiology customers, who were early adopters of its predecessor, LMS (Lesion Management Solution) product.

The recent opening of Median's operations in Hong Kong, Tokyo and Shanghai, as well as the skyrocketing development of Median's Boston-based subsidiary, will strengthen, re-engage and scale the KOL networks of the company for the Patient Care business lines, worldwide. Median intends to continue closely collaborate with FURUI, its Chinese investor and partner to help develop KOL networks and to develop medical partnerships with major hospital and cancer centers aiming at positioning MediScan® as the reference medical device for major programs dedicated to cancer screening, detection, diagnosis and monitoring in China.

Future releases of MediScan® include the integration of new technology based on the latest advances in artificial intelligence, cloud computing and Big Data analytics.

"MediScan® is a critical part of Median's commitment to improving care for patients worldwide. We believe that MediScan® fills a huge unmet need in helping governments and healthcare systems to efficiently and accurately screen, detect, help diagnose, and monitor patients at risk for and those living with cancer. It underscores Median's core value of helping patients in need," said Jeanne Hecht, COO of Median Technologies.

MediScan® is a registered trademark of Median Technologies.​


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ovum AI launches Australia’s first longitudinal dataset to revolutionize women’s healthcare